Tie

Tie Related Products (24):

By Effects:	Inhibitors (14) Antagonist (1) Activators (5)

Cat. No.	Product Name	Effect	Purity

HY-109041

Razuprotafib	Activator	98.0%
Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM).

HY-16782

Pexmetinib	Inhibitor	99.81%
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-P99036

Nesvacumab	Inhibitor	99.11%
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches.

HY-P10580

Vasculotide	Activator	99.84%
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.

HY-P99330

Vanucizumab	Inhibitor
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects.

HY-109041A

Razuprotafib sodium	Activator
Razuprotafib (AKB-9778) sodium is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib sodium promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib sodium inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib sodium shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM).

HY-P10580A

Vasculotide TFA	Activator	99.88%
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.

HY-P99546

Trebananib	Inhibitor	≥99.0%
Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities.

HY-P99510

Zansecimab	Inhibitor
Zansecimab (LY-3127804) is a monoclonal antibody against angiopoietin 2 (Ang‑2). Zansecimab can be used in research on angiogenesis, immunomodulation and anti-tumor activity.

HY-E70782

TIE2 R849W Recombinant Human Active Protein Kinase
TIE2 plays an important role in vascular formation and maintenance. Mutations in TIE2 lead to vascular malformations, which are painful vascular lesions that cause disfigurement, bleeding, and thrombosis. TIE2 R849W is the most common mutation implicated in an inherited form of vascular malformations. TIE2 R849W Recombinant Human Active Protein Kinase is a recombinant TIE2 R849W protein that can be used to study TIE2 R849W-related functions.

HY-10331AR

Regorafenib monohydrate (Standard)	Inhibitor
Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.

HY-E70784

TIE2 Y897S Recombinant Human Active Protein Kinase
TIE2 plays an important role in vascular formation and maintenance. Mutations in TIE2 lead to vascular malformations, which are painful vascular lesions that cause disfigurement, bleeding, and thrombosis. TIE2 Y897S is the most mutation of TIE2. TIE2 Y897S Recombinant Human Active Protein Kinase is a recombinant TIE2 Y897S protein that can be used to study TIE2 Y897S-related functions.

HY-P991663

AMG-780	Inhibitor
AMG-780 is a fully human IgG2 antibody that targets angiopoietin 1 (Ang1) (IC₅₀ = 4.5 nM) and angiopoietin 2 (Ang2) (IC₅₀ = 0.06 nM). AMG-780 inhibits tumor growth in the Colo205 xenograft mouse model by inhibiting both Ang1 and Ang2. AMG-780 is indicated for the research of cancers such as colon cancer.

HY-160708

Tie2 kinase inhibitor 3	Inhibitor
Tie2 kinase inhibitor 3 (compound 63) is a potent Tie-2 kinase inhibitor with good oral activity (IC₅₀=30 nM). Tie2 kinase inhibitor 3 inhibits phosphorylation and signaling of Tie-2 by competing with the ATP binding site of Tie-2 kinase. This inhibition affects the stability and maturity of blood vessels, which has an impact on tumor angiogenesis. Tie2 kinase inhibitor 3 can be used to restrict tumor growth and regulate angiogenesis.

HY-E70783

TIE2 Y1108F Recombinant Human Active Protein Kinase
TIE2 plays an important role in vascular formation and maintenance. Mutations in TIE2 lead to vascular malformations, which are painful vascular lesions that cause disfigurement, bleeding, and thrombosis. TIE2 Y1108F is the most mutation of TIE2. TIE2 Y1108F Recombinant Human Active Protein Kinase is a recombinant TIE2 Y1108F protein that can be used to study TIE2 Y1108F-related functions.

HY-P991385

UBX2050	Inhibitor
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research.

HY-N3634

Corylifol C
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively.

HY-P991384

DX-2240	Inhibitor
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors).

HY-16782R

Pexmetinib (Standard)	Inhibitor
Pexmetinib (Standard) is the analytical standard of Pexmetinib. This product is intended for research and analytical applications. Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-100556R

Tie2 kinase inhibitor 1 (Standard)	Inhibitor
Tie2 kinase inhibitor 1 (Standard) is the analytical standard of Tie2 kinase inhibitor 1 (HY-100556). This product is intended for research and analytical applications. Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM. Tie2 kinase inhibitor 1 has anti-cancer activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.